CBD Life Sciences Inc. (CBDL) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist CBD Life Sciences Inc. (CBDL) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 41/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026CBD Life Sciences Inc. (CBDL) Gesundheitswesen & Pipeline-Uebersicht
CBD Life Sciences Inc. is a small healthcare company focused on developing and marketing cannabidiol (CBD) based organic products, including hemp drops, massage oils, and pet products. Operating in the specialty and generic drug manufacturing industry, the company faces challenges with profitability and market competition.
Investmentthese
Investing in CBD Life Sciences Inc. (CBDL) presents significant risks due to its current financial standing and competitive landscape. With a negative profit margin of -905.5% and a negative gross margin of -9.9%, the company's financial viability is questionable. The company's high beta of -3603.52 indicates extreme volatility, making it a speculative investment. Potential growth catalysts include successful product innovation and market expansion, but these are highly uncertain. The company's small size, with only 3 employees, limits its operational capacity. Investors should carefully consider these factors and conduct thorough due diligence before considering an investment in CBDL. The lack of a dividend yield further reduces the attractiveness of the stock for income-seeking investors.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
- P/E ratio of -0.64 reflects negative earnings, suggesting the company is not currently profitable.
- Profit Margin of -905.5% highlights significant operational inefficiencies and challenges in generating profit.
- Gross Margin of -9.9% indicates that the company's cost of goods sold exceeds its revenue, posing a threat to long-term sustainability.
- Beta of -3603.52 suggests the stock is highly volatile and moves inversely to the market, increasing investment risk.
Wettbewerber & Vergleichsunternehmen
Staerken
- Focus on cannabidiol (CBD) based organic products.
- Diverse product line including hemp drops, massage oils, and pet products.
- Potential for growth in the expanding CBD market.
Schwaechen
- Negative profit margin of -905.5%.
- Negative gross margin of -9.9%.
- Small number of employees (3), limiting operational capacity.
- High beta of -3603.52 indicating extreme volatility.
Katalysatoren
- Upcoming: Potential regulatory changes in the CBD market could create new opportunities or challenges.
- Ongoing: Increasing consumer awareness and acceptance of CBD products may drive demand.
- Ongoing: Development and launch of new CBD-infused products targeting specific health conditions.
- Ongoing: Strategic partnerships with established healthcare or retail companies to expand market reach.
Risiken
- Potential: Intense competition in the CBD market could erode market share and profitability.
- Ongoing: Regulatory uncertainty and varying state laws create compliance challenges.
- Potential: Changes in consumer preferences or negative publicity could reduce demand for CBD products.
- Ongoing: The company's negative profit and gross margins pose a threat to its financial sustainability.
- Potential: Limited access to capital may hinder growth and expansion efforts.
Wachstumschancen
- Expansion of Product Line: CBD Life Sciences can expand its product line to include new CBD-infused products targeting specific health conditions or wellness needs. The market for CBD products is projected to reach $16 billion by 2026, providing ample opportunity for growth. Success depends on effective research and development to create innovative and differentiated products, giving the company a competitive edge.
- Strategic Partnerships: Forming strategic partnerships with established healthcare or retail companies can provide CBD Life Sciences with access to new markets and distribution channels. Collaborating with larger companies can enhance brand visibility and credibility. The timeline for realizing benefits from partnerships depends on the negotiation and implementation process, but strategic alliances can drive growth within the next 1-2 years.
- Online Sales and Marketing: Enhancing its online presence and marketing efforts can help CBD Life Sciences reach a broader customer base. Investing in e-commerce platforms, social media marketing, and search engine optimization can drive online sales. The global e-commerce market is expected to continue growing, offering significant opportunities for CBD Life Sciences to expand its online sales channels and increase revenue.
- International Expansion: Expanding into international markets, particularly in Europe and Asia, can provide CBD Life Sciences with new growth opportunities. The global market for CBD products is expanding, and entering new geographic regions can diversify revenue streams. However, international expansion requires careful consideration of regulatory requirements and cultural differences, which may take 2-3 years to fully implement.
- Focus on Pet Products: The market for CBD pet products is growing rapidly, as pet owners seek natural solutions for their animals' health and wellness. CBD Life Sciences can capitalize on this trend by expanding its line of pet products and marketing them to pet owners. The pet care industry is expected to continue growing, providing a favorable environment for CBD Life Sciences to increase its market share in the pet product segment.
Chancen
- Expansion of product line to target specific health conditions.
- Strategic partnerships with established healthcare or retail companies.
- Increased online sales and marketing efforts.
- Expansion into international markets.
Risiken
- Intense competition in the CBD market.
- Regulatory uncertainty and varying state laws.
- Potential changes in consumer preferences.
- Economic downturn affecting consumer spending.
Wettbewerbsvorteile
- Proprietary formulations for CBD-infused products.
- Focus on organic and natural ingredients.
- Brand reputation for quality and effectiveness (if established).
Ueber CBDL
CBD Life Sciences Inc., based in Scottsdale, Arizona, develops and markets a range of cannabidiol (CBD) based organic products. The company's offerings include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. Founded to capitalize on the growing market for CBD-infused products, CBD Life Sciences aims to provide consumers with natural and organic alternatives for various health and wellness needs. The company focuses on creating products that leverage the potential therapeutic benefits of CBD. Its product line targets a diverse set of consumer needs, from pain relief and anxiety management to sleep improvement and pet care. CBD Life Sciences operates within the broader healthcare sector, specifically in the specialty and generic drug manufacturing industry, adapting its product offerings to meet evolving consumer preferences and regulatory requirements. Despite its efforts to establish a presence in the CBD market, CBD Life Sciences faces significant challenges, including negative profit margins and intense competition. The company's ability to navigate these challenges and achieve sustainable growth will depend on its success in product innovation, marketing effectiveness, and operational efficiency.
Was das Unternehmen tut
- Develops cannabidiol (CBD) based organic products.
- Markets hemp drops for general wellness.
- Offers massage oils for relaxation and therapeutic purposes.
- Provides recovery pain relief creams for muscle and joint pain.
- Sells anxiety and sleep solutions supplements.
- Markets CBD-infused edibles.
- Offers a line of pet products containing CBD.
Geschaeftsmodell
- Develops and manufactures CBD-based products.
- Markets products directly to consumers through online channels.
- Generates revenue through the sale of CBD-infused products.
Branchenkontext
CBD Life Sciences Inc. operates in the rapidly evolving market for cannabidiol (CBD) products. The industry has experienced substantial growth due to increasing consumer interest in natural health and wellness solutions. However, the market is highly competitive, with numerous companies offering similar products. Regulatory uncertainty and varying state laws add complexity to the business environment. CBD Life Sciences competes with both established pharmaceutical companies and smaller, specialized CBD product manufacturers. The company's success depends on its ability to differentiate its products and navigate the complex regulatory landscape.
Wichtige Kunden
- Individuals seeking natural health and wellness solutions.
- Consumers looking for pain relief and anxiety management products.
- Pet owners seeking CBD products for their pets.
Finanzdaten
Chart & Info
CBD Life Sciences Inc. (CBDL) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 24. März 2020
-
Stocks That Hit 52-Week Lows On Thursday
· 27. Feb. 2020
-
Stocks That Hit 52-Week Lows On Thursday
· 30. Jan. 2020
-
Stocks That Hit 52-Week Lows On Thursday
· 5. Dez. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CBDL.
Kursziele
Wall-Street-Kurszielanalyse fuer CBDL.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CBDL auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Lisa Anne Nelson
CEO
Lisa Anne Nelson serves as the CEO of CBD Life Sciences Inc. Her leadership experience involves managing small teams and guiding the company's strategic direction in the competitive CBD market. Nelson's background includes overseeing the development and marketing of CBD-based organic products, focusing on hemp drops, massage oils, and other wellness solutions. Her role requires navigating the regulatory landscape and adapting to evolving consumer preferences within the healthcare sector.
Erfolgsbilanz: Under Lisa Anne Nelson's leadership, CBD Life Sciences Inc. has focused on expanding its product line and reaching new markets. Key milestones include the introduction of CBD-infused pet products and the development of anxiety and sleep solutions supplements. However, the company continues to face challenges related to profitability and market competition, as reflected in its negative profit and gross margins.
CBDL OTC-Marktinformationen
The OTC Other tier represents the lowest tier of over-the-counter (OTC) markets, indicating that CBD Life Sciences Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like NYSE or NASDAQ due to the lack of stringent listing requirements and oversight.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases investment risk.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- Higher potential for fraud or manipulation due to less regulatory oversight.
- OTC Other tier companies may have difficulty raising capital.
- Potential delisting or trading suspension due to non-compliance.
- Verify the company's legal status and registration.
- Review available financial statements and SEC filings.
- Assess the company's management team and their experience.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive position and industry trends.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- Company registration with state authorities.
- Existence of a functional website and contact information.
- Publicly available information about the company's products and services.
- Presence of a management team and board of directors.
- Any news coverage or press releases about the company.
CBD Life Sciences Inc. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for CBDL?
CBD Life Sciences Inc. (CBDL) currently holds an AI score of 41/100, indicating low score. Key strength: Focus on cannabidiol (CBD) based organic products.. Primary risk to monitor: Potential: Intense competition in the CBD market could erode market share and profitability.. This is not financial advice.
How frequently does CBDL data refresh on this page?
CBDL prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CBDL's recent stock price performance?
Recent price movement in CBD Life Sciences Inc. (CBDL) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on cannabidiol (CBD) based organic products.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CBDL overvalued or undervalued right now?
Determining whether CBD Life Sciences Inc. (CBDL) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CBDL?
Before investing in CBD Life Sciences Inc. (CBDL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CBDL to a portfolio?
Potential reasons to consider CBD Life Sciences Inc. (CBDL) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Focus on cannabidiol (CBD) based organic products.. Additionally: Diverse product line including hemp drops, massage oils, and pet products.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CBDL?
Yes, most major brokerages offer fractional shares of CBD Life Sciences Inc. (CBDL) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CBDL's earnings and financial reports?
CBD Life Sciences Inc. (CBDL) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CBDL earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data is limited and may not be fully accurate.
- OTC market investments carry higher risks than exchange-listed stocks.
- The CBD market is subject to regulatory changes and uncertainty.